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Background: The translocation t(1;19)(q23;p13), which results in the TCF3-PBX1 chimeric gene, is one of the most
frequent rearrangements observed in B cell acute lymphoblastic leukemia. It appears in both adult and pediatric
patients with B cell acute lymphoblastic leukemia at an overall frequency of 3 to 5%. Most cases of pre-B cell acute
lymphoblastic leukemia carrying the translocation t(1;19) have a typical immunophenotype with homogeneous
expression of CD19, CD10, CD9, complete absence of CD34, and at least diminished CD20. Moreover, the
translocation t(1;19) correlates with known clinical high risk factors, such as elevated white blood cell count, high
serum lactate dehydrogenase levels, and central nervous system involvement; early reports indicated that patients
with translocation t(1;19) had a poor outcome under standard treatment.
Case presentation: We report the case of a 15-year-old Syrian boy with pre-B cell acute lymphoblastic leukemia
with abnormal karyotype with a der(19)t(1;19)(q21.1;p13.3) and two yet unreported chromosomal aberrations: an
interstitial deletion 6q12 to 6q26 and a der(13)t(1;13)(q21.1;p13). According to the literature, cases who are
translocation t(1;19)-positive have a significantly higher incidence of central nervous system relapse than patients
with acute lymphoblastic leukemia without the translocation. Of interest, central nervous system involvement was
also seen in our patient.
Conclusions: To the best of our knowledge, this is the first case of childhood pre-B cell acute lymphoblastic
leukemia with an unbalanced translocation t(1;19) with two additional chromosomal aberrations, del(6)(q12q26) and
t(1;13)(q21.3;p13), which seem to be recurrent and could influence clinical outcome. Also the present case confirms
the impact of the translocation t(1;19) on central nervous system relapse, which should be studied for underlying
mechanisms in future.
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Translocation t(1;19)(q23;p13) is a repeatedly but overall
rarely observed rearrangement in B cell acute lympho-
blastic leukemia (B-ALL), and can be found in both
adult and pediatric patients at an overall frequency of 3
to 5% [1, 2]. Most cases of pre-B-ALL carrying the trans-
location t(1;19) express a typical immunophenotype
with homogeneous expression of CD19, CD10, CD9,
complete absence of CD34, and reduced expression of
CD20 [3]. This translocation can occur in two forms: a
balanced or an unbalanced one. The unbalanced form of
pre-B-ALL leads to a derivative of chromosome 19 [2].
Both the balanced and the unbalanced translocations
t(1;19) result in the fusion of transcription factor 3
(TCF3) located in 19p13 with pre-B cell leukemia
homeobox 1 (PBX1) in 1q23, to form a chimeric gene
whose protein product alters, among other cellular pro-
cesses, cell differentiation arrest [1]. Specifically, the
fusion gene encodes for a transcription factor bearing the
transactivation domain of TCF3 and the deoxyribonucleic
acid (DNA)-binding domain of PBX1, which facilitates
genes constitutive activation [4]. In addition, the fusion
protein appears to have a dominant negative effect on the
wild-type TCF3 activity. So both increased expression of
PBX1 target genes and reduction in TCF3 activity are
thought to be important in leukemogenesis [5].
Other partner genes of TCF3 include ZNF384 (12p13;
prognosis unknown), NOL1 (12p13; prognosis un-
known), an unknown partner gene in 13q14 (prognosis
unknown), HLF (17q22; extremely poor prognosis), and
FB1/TFPT (19q13.4; prognosis unknown) [6–8]. More-
over, the translocation t(1;19) correlates with known
clinical high risk features, such as elevated white blood
cell (WBC) count, high serum lactate dehydrogenase
(LDH) levels, central nervous system (CNS) involve-
ment, and poor outcome under standard treatment [9].
Here we report the clinical, G-banding, and molecular
cytogenetic results obtained in a childhood patient with
pre-B-ALL with an unbalanced translocation t(1;19) and
two additional chromosomal aberrations.
Case presentation
On 22 May 2014, a 15-year-old Syrian boy without sig-
nificant personal or familial history of malignancies pre-
sented to Al-Biruni University Hospital with a 1-month
history of bleeding gums, fatigue, and pallor. He had no
familial history of malignancies and no social and envir-
onmental history or exposure to toxins and animals. A
physical examination revealed splenomegaly without
lymph node involvement. An initial laboratory evalu-
ation of peripheral blood (PB) revealed elevated WBC
count of 56×109/l with 94% of blasts cells, anemia (9.1
g/dL), and a thrombocytopenia (123×109/L). His serum
LDH value was 862 U/l (normal value up to 480 U/l).He was diagnosed as having pre-B-ALL according to the
World Health Organization (WHO) classification. A
biopsy of his bone marrow (BM) revealed hypercellular
marrow (WBC count 155.3×109/l with 94% of blasts
cells).
He was referred (on 25 May 2014) to our Chromo-
somes Laboratory and Flow-cytometry Laboratory,
Molecular Biology and Biotechnology Department,
Atomic Energy Commission of Syria, for cytogenetics
and flow-cytometric analyses. He could be classified in a
high risk group. Thus, he was supplied with German
Multicenter Study Group for Adult Acute Lymphoblastic
Leukemia (GMALL) protocol treatment after the initial
diagnosis for 5 months. Unfortunately, due to the polit-
ical situation in his home country he was given available
drugs such as vincristine 1.4 mg/m2, doxorubicin 25 mg/
m2, and methotrexate 20 mg/m2. He responded to that
treatment without any infiltrations in his BM; he re-
ceived platelets and blood transfusions many times; his
PB showed pancytopenia and neutropenia. The treat-
ment was stopped before consolidation phase because
his BM biopsy evaluation showed morphologic remission
(8% blasts left); a cerebrospinal fluid test revealed abnor-
mal cells; he also had a pulmonary infection. Approxi-
mately 5.5 months after initial diagnosis he died due to
unknown causes while under treatment. No autopsy was
performed because he died in his house. His parents
agreed with the scientific evaluation of the case and a
study was approved by the ethical committee of the
Atomic Energy Commission, Damascus, Syria.
A chromosome analysis on a BM sample using GTG-
banding according to standard procedures [10] was
performed before his treatment started; it revealed a karyo-
type of 46,XY,del(6)(q?),der(13)t(1;13),der(19)t(1;19)[6]/46,X
Y,del(6)(q?),der(19)t(1;19)[5]/47,XY,+i(1)(q?),del(6)(q?),der
(19)t(1;19)[1]/46,XY[6] (Fig. 1). Karyotype was described
according to the International System for Human Cyto-
genetic Nomenclature (ISCN) of 2013 [11].
Further studies were performed on BM sample using
molecular cytogenetics (Fig. 2). We performed dual-
color fluorescence in situ hybridization (D-FISH) with
specific whole chromosome paint (WCP) probes for
chromosomes 1, 6, 13, and 19 (MetaSystems, Altlus-
sheim, Germany) [10], which did not provide any infor-
mation on the cryptic translocations (data not shown),
and array-proven high-resolution multicolor banding
(aMCB) [12], using probes for the corresponding chro-
mosomes 1, 6, 13, and 19 involved according to GTG-
banding (Fig. 2). Reverse transcriptase-polymerase chain
reaction (RT-PCR) for E2A-PBX1 fusion transcripts was
performed prior the treatment using specific primers
previously described [13], confirmed the presence of the
TCF3/PBX1 fusion (E2A/PBX1 transcript; 373-base pair
band), most often identified in acute lymphoblastic
Fig. 1 GTG-banding revealed the following karyotype in 6/18 metaphases: 46,XY,del(6)(q?),der(13)t(1;13),der(19)t(1;19)[6]. All derivative
chromosomes are marked and highlighted by arrow heads
Fig. 2 Array-proven multicolor banding results are shown. The normal chromosomes (#) are depicted on the left side of each image and the derivative
of the four chromosomes on the right side of normal chromosomes. The unstained regions when suing chromosome-specific array-proven multicolor
banding probe sets on the derivative chromosomes are shown in gray. a Different pseudocolor depictions for array-proven multicolor banding1 probe
set revealed the breakpoints in derivative chromosomes 13, 19 and isochromosome 1q. b Array-proven multicolor banding6 uncovered the interstitial
deletion in der(6). c Array-proven multicolor banding13 revealed that practically the whole short arm of chromosome 13 remained intact
in the der(13). d The breakpoint on der(19) could be determined by multicolor banding19 probe set. # chromosome, der derivative
chromosome, MCB multicolor banding
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karyotype prior to treatment was determined using a
fluorescence microscope (AxioImager.Z1 mot, Carl Zeiss
Ltd, Hertfordshire, UK) equipped with appropriate filter
sets to discriminate between a maximum of five fluoro-
chromes plus the counterstain 4',6-diamidino-2-phe-
nylindole (DAPI). Image capture and processing were





Immunophenotyping was performed on BM sample
using a general panel of fluorescent antibodies against the
following antigens typical for different cell lineages and
cell types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10,
CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20,
CD22, CD23, CD32, CD33, CD34, CD38, CD41a, CD45,
CD56, CD57, CD64, CD103, CD117, CD123, CD138,
CD209, CD235a, and CD243; in addition, antibodies to
kappa and lambda light chains, IgD, surface-bound IgM
(sIgM), and human leukocyte antigen-antigen D related
(HLA-Dr) were tested. All antibodies were purchased
from BD Biosciences (San Jose CA, USA). Samples were
analyzed on a BD FACSCalibur™ flow cytometer. Autoflu-
orescence, viability, and isotype controls were included.
Flow cytometric data acquisition and analysis were
conducted by BD Cellquest™ Pro software. Flow cytomet-
ric analysis of BM specimen characterized this case as
pre-B-ALL according to WHO classifications. The abnor-
mal cell population (94% of tested cells) was positive for
CD45+dim, CD19+, CD10+, HLA-DR+, and CD79a+. This
cell population was negative for CD34, CD2, CD7, CD13,
CD14, CD15, CD20, CD33, and CD117.
Discussion
According to the literature, the translocation t(1;19)(q23;p13)
is a translocation that is repeatedly but, overall, rarely
seen in B-ALL cases; it generates the TCF3-PBX1 fusion
gene [1, 2]. According to Mitelman Database of Chromo-
some Aberrations in Cancer [14], there are five cases of
ALL with translocation t(1;19)(q21;p13), seven such cases
with translocation t(1;13) involving short and/or long
arms of both chromosomes, five cases of ALL with iso-
chromosome i(1)(q10), and 710 cases of ALLs with
del(6)(q) including 21 cases with del(6)(q12) and three
cases with del(6)(q26). In addition, the chromosomal
bands 1q21, 13p13, and 19p13 are involved in chromo-
somal rearrangements in 252, 785, and eight cases, re-
spectively [14]. To the best of our knowledge, the present
case report is the first one to observe a childhood pre-B-
ALL with unbalanced translocation t(1;19)(q21.1;p13.3)
associated with two additional chromosomal aberrations
del(6)(q12q26) and der(13)t(1;13)(q21.1;p13) [14]. Ofinterest, one metaphase with an isochromosome 1q was
also observed in GTG-banding and found in 1/25 meta-
phases in fluorescence in situ hybridization (FISH) ana-
lyses too (Fig. 2). As aforementioned this was also seen in
five earlier cases of ALL [14].
The translocation t(1;19)(q23;p13) can be observed in
two principal forms [2, 15, 16]. Abnormalities of
chromosome 1, such as complete or partial trisomies for
the long arm, are known to arise during clonal evolution
and can be observed as recurrent in hematologic malig-
nancies [16–18].
The CKS1B gene mapped at 1q21 is a member of the
highly conserved cyclin kinase subunit 1 (CKS1) protein
family that interacts with cyclin-dependent kinases
(Cdks) and plays a critical role in cell cycle progression
[19]. CKS1B overexpression is correlated with low p27
expression and adverse survival in several human malig-
nancies including gastric, colorectal, and oral squamous
cell carcinomas [20–22] because of its critical role as a
cell cycle regulator and its involvement in various hu-
man carcinomas.
This 6q12-22 area contains several genes with a known
or suspected tumor-suppressing function including
MAP3K7, for which a tumor-suppressive role for pros-
tate epithelial cells has recently been demonstrated [23].
MAP3K7 is ubiquitary expressed and involved in various
biological processes such as cell growth, differentiation,
and apoptosis. MAP3K7 exerts these effects by interact-
ing with a number of different signaling pathways and
activator molecules [24–27].
In contrast to early reports on patients with transloca-
tion t(1;19) reporting a more adverse outcome for
patients with balanced translocation compared with pa-
tients with an unbalanced translocation t(1;19) [28–30],
more recent studies found no difference in event-free
survival (EFS) among these two subgroups [30–32].
However, cases who are translocation t(1;19)-positive
have a significantly higher incidence of CNS involvement
in cases of relapse than patients with ALL without the
translocation [30]; the St Jude’s group observed four
patients with CNS relapse but no patients with BM re-
lapse among 41 patients with translocation t(1;19) [33].
Also, Moorman et al. [34] reported six relapses in 50 pa-
tients with translocation t(1;19) of which three relapses
involved the CNS. Moreover, CNS disease was found to
be more common in patients with T cell acute lympho-
blastic leukemia (T-ALL) compared with those with
pre-B-ALL [35], and CNS involvement was associated
with poor survival. Fielding et al. [36] showed as well
that the outcome of relapsing patients was very poor,
and that patients with T cell disease had only a 5%
5-year survival compared with 8% in those with B-ALL.
Additional cytogenetic abnormalities (ACAs) were ob-
served in 63% (47 out of 2640, which is 1.8%, children
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ences between translocation t(1;19) and/or der(19)t(1;19)-
positive cases [37]. The most common ACAs were
del(9p), i(9q), del(6q), and del(13q) [16, 20]. None of their
47 patients with translocation t(1;19) demonstrated con-
comitant aberrations of 13p13 and/or 6q12 to 6q26 re-
gions. Thus, the clinical significance of an unbalanced
translocation t(1;19)(q21.1;p13.3) in our patient with a
13p13 translocation and/or del(6)(q12q26) is unclear. Ac-
cording to the literature the presence of ACAs has no sig-
nificant impact on EFS or overall survival [35]. This
observation is in line with findings from other recurrent
leukemia-associated translocations, where ACAs seem to
have no influence on prognosis [37, 38]. Still, the adverse
outcome of the present case may be a hint that there are
exceptions to that rule.
Patients with pediatric ALL with WBC counts of more
than 50×109/l are considered to be at high risk of relapse
and thus receive intensive treatment [39, 40]. In retro-
spective analysis, patients with hyperleukocytosis (WBC
count >50×109/l) were significantly correlated with
shorter survival times. The cytogenetic features were
closely linked to the WBC and at least partly explain the
prognostic value of WBC, although there is evidence
that children with similar cytogenetic aberrations may
have very different WBCs [41–43].Conclusions
Here, we described the presence of two uncommon
chromosomal aberrations, that is, del(6)(q12q26) and
der(13)t(1;13)(q21.1;p13) in a case of childhood pre-B-ALL
with unbalanced translocation t(1;19), which might suggest
that special ACAs could have an adverse effect on clinical
outcome, in contrast to what is widely discussed at present.
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